This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Tenaya Therapeutics to Report TN-201 Data
Tech clinical trial data

Tenaya Therapeutics to Report TN-201 Data

Analysis based on 10 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026

Sentiment
20
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of new interim data for Tennessee State Route 201 by Tenaya Therapeutics is expected to directly impact the company's stock performance. Positive data could lead to a significant increase in investor confidence and stock value, while negative or inconclusive data could have the opposite effect.

Biotechnology Pharmaceuticals
Event Summary

Tenaya Therapeutics, a clinical-stage biotechnology company, announced that it will report new interim data from Cohort 1 and Cohort 2 of its MyPEAK-1 Phase 1b/2 trial for Tennessee State Route 201 gene therapy. This therapy is designed to treat Myosin binding protein C, cardiac-associated hypertrophic cardiomyopathy (HCM), a severe and progressive heart condition affecting approximately 120,000 patients in the United_States. Tennessee State Route 201 aims to deliver a working Myosin binding protein C, cardiac gene to heart muscle cells to increase MyBP-C protein levels, potentially halting or reversing the disease. The United States — Food and Drug Administration has granted Tennessee State Route 201 Fast Track, Orphan Drug, and Rare Pediatric Drug Designations, and the International — European Commission has also granted it orphan medicinal product status. The data will be presented on June 3, 2026, via a live webcast.

Entities Involved
stock
Tenaya Therapeutics
Tenaya Therapeutics is announcing new interim data from its MyPEAK-1 Phase 1b/2 trial for Tennessee State Route 201, which could significantly impact its stock price and future development of its gene therapy.
Importance 100.0 Sentiment 20.0
oth
Tennessee State Route 201
Tennessee State Route 201 is the gene therapy being developed by Tenaya Therapeutics for Myosin binding protein C, cardiac-associated hypertrophic cardiomyopathy, and its clinical trial data is the focus of this event.
Importance 90.0 Sentiment 20.0
oth
Myosin binding protein C, cardiac
Myosin binding protein C, cardiac is the gene associated with hypertrophic cardiomyopathy (HCM) that Tennessee State Route 201 gene therapy aims to address.
Importance 70.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration has granted Tennessee State Route 201 Fast Track, Orphan Drug, and Rare Pediatric Drug Designations, indicating regulatory recognition of the therapy's potential.
Importance 30.0 Sentiment 0.0
govactor
International — European Commission
The International — European Commission has granted Tennessee State Route 201 orphan medicinal product designation, which could facilitate its development and market access in Europe.
Importance 20.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ International — European Commission
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.